




2026 Advances in Prostate Cancer Management

A Multidisciplinary Approach

OCTOBER 8-9, 2026

HYBRID SYMPOSIUM • IN-PERSON & VIRTUAL



Memorial Sloan Kettering
Cancer Center



Overview

This two-day course, presented by faculty from Memorial Sloan Kettering Cancer Center (MSK), will highlight the latest advances in the multidisciplinary management of prostate cancer.

Through comprehensive, state-of-the-art lectures and interactive discussions, participants will engage with expert faculty spanning radiology, pathology, surgery, radiation oncology, and medical oncology to exchange insights and explore collaborative approaches to prostate cancer care.

Sessions will cover the full continuum of care, including patient evaluation and risk assessment, active surveillance, focal therapy, local and systemic therapies, and the prevention and management of treatment-related side effects. Participants will also gain insights into emerging research and innovations shaping the future of prostate cancer care, including the latest scientific discoveries and clinical advances from MSK.

Target Audience

This program is intended for urologists, urologic oncologists, medical oncologists, radiation oncologists, pathologists, radiologists, and allied health professionals involved in the care of patients with prostate cancer. Participants may choose to **attend onsite at MSK or virtually**. Visit the **Registration** section for more information.



Syllabus

Following the course, participants will receive access to an online syllabus containing recordings of the faculty presentations and PDF copies of the presentation slides.

Continuing Education Credit

This activity has been approved to offer *AMA PRA Category 1 Credit(s)*[™], ABIM Maintenance of Certification, and ABS Continuous Certification. Nursing Continuing Professional Development credit is pending. Visit the **Accreditation** section for more information.



Scan here for full details and registration
or visit. msk.org/ProstateCourse

Thursday Agenda

October 8, 2026 | 8:00 a.m.–5:00 p.m. ET

TIME	SESSIONS
7:30 a.m.	Onsite Check-in and Breakfast Virtual participants should plan to join at 7:55 a.m. for the start of the program.
8:00 a.m.	Welcome and Opening Remarks Behfar Ehdaie, MD, MPH
SESSION I	
Prostate Cancer Diagnosis and Staging	
Moderator: Behfar Ehdaie, MD, MPH	
8:15 a.m.	Prostate Cancer Screening in 2026: Advances in Risk Assessment and Early Detection Andrew Vickers, PhD
9:00 a.m.	Beyond an Elevated PSA: Integrating Genetics, Biomarkers, and Imaging Patrick Lewicki, MD, MS
9:30 a.m.	TUMOR BOARD Active Surveillance or Treatment? Navigating Complex Clinical Decisions Behfar Ehdaie, MD, MPH (Moderator) Jonathan S. Fainberg, MD, MPH Jose M. Flores, MD, MHA Andrew Vickers, PhD
10:30 a.m.	Break

SESSION II

Advanced Techniques and Emerging Technologies

Moderator: Behfar Ehdaie, MD, MPH

10:45 a.m.	Novel Robotic Technology in Urologic Oncology Alvin C. Goh, MD
11:15 a.m.	Advances in Prostate Biopsy: Techniques, Practical Pearls, and Billing Considerations Jonathan S. Fainberg, MD, MPH

- 11:45 a.m. **PANEL DISCUSSION**
Emerging Techniques in Robotic Prostatectomy and Focal Therapy
Behfar Ehdaie, MD, MPH (Moderator)
Jonathan S. Fainberg, MD, MPH
Alvin C. Goh, MD
Patrick Lewicki, MD, MS

12:30 p.m. Lunch Break

SESSION III

High-Risk Prostate Cancer

Moderator: Himanshu Nagar, MD, MS

- 1:15 p.m. **PANEL DISCUSSION**
Multidisciplinary Management of High-Risk Prostate Cancer: From Patient Selection to Treatment
Himanshu Nagar, MD, MS (Moderator)
Christopher Gaffney, MD
Thomas P. Kole, MD, PhD
Kristine Lacuna, MD
- 2:15 p.m. **Prostate Cancer Pathology: Cribriform and Intraductal Features and Gleason Grade Quantification**
Samson W. Fine, MD
- 3:00 p.m. Break
- 3:15 p.m. **DEBATE**
Localized Prostate Cancer Recurrence After Radiation: Salvage Cryotherapy vs. Salvage Radiation Therapy
Jonathan S. Fainberg, MD, MPH (Salvage Cryotherapy)
Daniel Gorovets, MD (Salvage Radiation Therapy)
- 4:00 p.m. **DEBATE**
Does a Negative PSMA PET Change the Role of Pelvic Lymph Node Dissection?
Michael J. Morris, MD (No)
Massimiliano Spaliviero, MD, FACS (Yes)
- 4:45 p.m. **Closing Remarks**
Behfar Ehdaie, MD, MPH

- 5:00–
6:00 p.m. **Networking Reception**
Enjoy hors d'oeuvres, refreshments, and an opportunity to connect with colleagues.

Friday Agenda

October 9, 2026 | 8:00 a.m.–4:00 p.m. ET

TIME	SESSIONS
7:30 a.m.	Onsite Check-in and Breakfast Virtual participants should plan to join at 7:55 a.m. for the start of the program.
8:00 a.m.	Welcome and Opening Remarks Michael J. Morris, MD
8:05 a.m.	 Keynote Address Christopher Barbieri, MD, PhD
8:50 a.m.	Q&A and Discussion

SESSION IV Locally Advanced Prostate Cancer

Moderator: Michael J. Morris, MD

9:00 a.m.	DEBATE Lymph Node–Positive Disease: Surgery vs. Radiation? Christopher Gaffney, MD (Surgery) James Robert Janopaul-Naylor, MD (Radiation)
9:45 a.m.	Break
10:00 a.m.	PANEL DISCUSSION Biochemical Recurrence (BCR): Evaluation and Management Sean McBride, MD, MPH (Moderator) Kristine Lacuna, MD Charles James Ryan, MD

SESSION V

Metastatic Androgen Pathway Modulation-Sensitive (APMS) Prostate Cancer

Moderator: Michael J. Morris, MD

10:40 a.m. **DEBATE**

Oligometastatic Disease: SBRT With or Without Systemic Therapy

Justin Haseltine, MD (SBRT Alone)

Eric Bent, MD, PhD (SBRT + Systemic Therapy)

11:20 a.m. **DEBATE**

First-Line Treatment for Unselected Metastatic Prostate Cancer: Radioligand Therapy vs. Chemotherapy

Michael J. Morris, MD (Radioligand Therapy)

Anis Hamid, MBBS, PhD (Chemotherapy)

12:00 p.m. **DEBATE**

PARP Inhibition in Metastatic APMS Disease: Should We Treat Beyond BRCA2?

Kristine Lacuna, MD (BRCA2 Only)

Karen A. Autio, MD, MSc (Beyond BRCA2)

12:40 p.m. Lunch Break

SESSION VI

Androgen Pathway Modulator-Resistant (APMR) Prostate Cancer

Moderator: Michael J. Morris, MD

1:30 p.m. **DEBATE**

First-Line Treatment for APMR Disease: Radioligand Therapy vs. Chemotherapy

Lisa Bodei, MD, PhD (Radioligand Therapy First)

Salomon Tendler, MD, PhD (Chemotherapy First)

2:10 p.m. **Immunotherapy for Prostate Cancer:
Coming of Age**


Susan F. Slovin, MD, PhD

SESSION VII

Neuroendocrine Prostate Cancer (NEPC)

Moderator: Michael J. Morris, MD

2:40 p.m.



Keynote Address

NEPC: Evolving Treatment Strategies

Himisha Beltran, MD

3:20 p.m.

Q&A and Discussion

3:30 p.m.

PANEL DISCUSSION

Management of NEPC

Michael J. Morris, MD (Moderator)

Karen A. Autio, MD, MSc

Matthew Dallos, MD

Charles James Ryan, MD

Salomon Tendler, MD, PhD

Himisha Beltran, MD

3:50 p.m.

Closing Remarks

Behfar Ehdaie, MD, MPH

Michael J. Morris, MD

Himanshu Nagar, MD, MS

4:00 p.m.

Adjournment



Scan here for full details and registration
or visit. msk.org/ProstateCourse


Course Faculty

MSK Course Directors



Behfar Ehdaie, MD, MPH

Associate Attending
Urology Service
Department of Surgery



Michael J. Morris, MD

Steven A. Greenberg Chair in Prostate Cancer Research
Attending; Prostate Cancer Section Head
Genitourinary Oncology Service
Department of Medicine



Himanshu Nagar, MD, MS

Director, Genitourinary Program
Manhattan Chief of External Beam Radiotherapy
Department of Radiation Oncology

Invited Keynote Speakers



Christopher Barbieri, MD, PhD

Attending Urologist
New York-Presbyterian Hospital
Professor of Urology; Bernard and Josephine Chaus
Professor of Urological Oncology
Weill Cornell Medical College, Cornell University



Himisha Beltran, MD

Professor of Medicine
Lank Center for Genitourinary Oncology
Division of Molecular and Cellular Oncology
Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School


Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships are mitigated prior to the commencement of the activity.

MSK Course Faculty



Karen A. Autio, MD, MSc

Assistant Attending
Genitourinary Oncology Service
Department of Medicine



Eric Bent, MD, PhD

Assistant Attending
External Beam Radiotherapy Service
Department of Radiation Oncology



Lisa Bodei, MD, PhD

Director of Targeted Radionuclide Therapy
Attending
Molecular Imaging and Therapy Service
Department of Radiology



Matthew Dallos, MD

Assistant Attending
Genitourinary Oncology Service
Department of Medicine



Jonathan S. Fainberg, MD, MPH

Assistant Attending
Urology Service
Department of Surgery




Samson W. Fine, MD

Attending
Department of Pathology and Laboratory Medicine




Jose M. Flores, MD, MHA

Assistant Attending
Urology Service
Department of Surgery



Christopher Gaffney, MD

Assistant Attending
Urology Service
Department of Surgery



Alvin C. Goh, MD

Director, Robotic Urologic Surgery Technology and Education
Associate Attending
Urology Service
Department of Surgery



Daniel Gorovets, MD

Associate Attending
External Beam Radiotherapy Service
Department of Radiation Oncology




Anis Hamid, MBBS, PhD

Assistant Attending
Genitourinary Oncology Service
Department of Medicine




Justin Haseltine, MD

Assistant Attending
External Beam Radiotherapy Service
Department of Radiation Oncology




James Robert Janopaul-Naylor, MD

Assistant Attending
External Beam Radiotherapy Service
Department of Radiation Oncology




Thomas P. Kole, MD, PhD

Associate Attending
External Beam Radiotherapy Service
Department of Radiation Oncology




Kristine Lacuna, MD

Assistant Attending
Genitourinary Oncology Service
Department of Medicine



Patrick Lewicki, MD, MS

Assistant Attending
Urology Service
Department of Surgery



Sean McBride, MD, MPH

Associate Attending
External Beam Radiotherapy Service
Department of Radiation Oncology




Charles James Ryan, MD

Attending
Genitourinary Oncology Service
Department of Medicine




Susan F. Slovin, MD, PhD

Associate Vice Chair, Academic Affairs
Attending
Genitourinary Oncology Service
Department of Medicine



Massimiliano Spaliviero, MD, FACS

Associate Attending
Urology Service
Department of Surgery



Salomon Tendler, MD, PhD

Assistant Attending
Genitourinary Oncology Service
Department of Medicine



Andrew Vickers, PhD

Attending Member
Department of Epidemiology and Biostatistics
Department of Medicine



Memorial Sloan Kettering
Cancer Center



Objectives

At the conclusion of this course, learners will be able to:

- Evaluate contemporary evidence and guideline recommendations for the management of localized and advanced prostate cancer, including active surveillance, focal therapy, surgery, radiation therapy, and systemic treatment options.
- Apply clinical, pathologic, genomic, and imaging data to risk stratification and individualized treatment planning for patients across the prostate cancer disease continuum.
- Interpret the appropriate use and clinical implications of genomic testing, biomarkers, and PSMA PET imaging to support diagnostic, prognostic, and therapeutic decision-making.
- Compare and select evidence-based treatment strategies for patients with advanced prostate cancer, including the integration and sequencing of emerging systemic therapies.
- Integrate multidisciplinary perspectives from urology, medical oncology, radiation oncology, radiology, and pathology to optimize patient-centered prostate cancer care and improve clinical outcomes.

Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **14.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

- 14.00 Medical Knowledge MOC Points in the American Board of Internal Medicine's Maintenance (**ABIM**) of Certification Assessment Recognition program; and
- 14.00 Accredited CME and Self-Assessment MOC points in the American Board of Surgery's (**ABS**) Continuous Certification program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABS MOC credit.

ANCC CNE Statement

Memorial Sloan Kettering Cancer Center–Nursing Professional Development / Continuing Education is accredited with distinction as a provider of nursing continuing professional development (NCPD) by the American Nurses Credentialing Center's Commission on Accreditation.

14.00 contact hours will be awarded to participants who attend the program in its entirety and complete a program evaluation.

Partial credit not awarded.



Registration

Early discounted rates are available through August 13, 2026.

Early Rates

- Physicians (MDs, PhDs, DOs): \$500
- Advanced Practice Providers: \$350
- Nurses and Other Healthcare Professionals: \$300
- Residents and Fellows: \$100
- Industry Professionals: Not applicable (general rates apply)*

General Rates (After August 13, 2026)

- Physicians (MDs, PhDs, DOs): \$600
- Advanced Practice Providers: \$450
- Nurses and Other Healthcare Professionals: \$400
- Residents and Fellows: \$200
- Industry Professionals: \$1,050*

MSK employees receive complimentary registration for all CME programs by signing in with MSK credentials (SSO).

Discounted registration is available for select groups, including students, MSK alumni/affiliates, and participants from low- and lower-middle-income countries. For additional details, visit the course website.

*An **industry professional** is defined as any individual, irrespective of their provider type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company.



Scan here for full details and registration
or visit. [**msk.org/ProstateCourse**](https://msk.org/ProstateCourse)



Memorial Sloan Kettering
Cancer Center

Continuing Medical Education

VISIT US ONLINE

msk.org/cme

[Instagram/MSKcontinuingmedicaleducation](https://www.instagram.com/MSKcontinuingmedicaleducation)

[LinkedIn /showcase/MSK-CME](https://www.linkedin.com/showcase/MSK-CME)

[Facebook/MSKCME](https://www.facebook.com/MSKCME)

[X/MSKCME](https://twitter.com/MSKCME)